PH12014502326B1 - A composition compromising amlodipine and losartan having an improved stability - Google Patents

A composition compromising amlodipine and losartan having an improved stability

Info

Publication number
PH12014502326B1
PH12014502326B1 PH12014502326A PH12014502326A PH12014502326B1 PH 12014502326 B1 PH12014502326 B1 PH 12014502326B1 PH 12014502326 A PH12014502326 A PH 12014502326A PH 12014502326 A PH12014502326 A PH 12014502326A PH 12014502326 B1 PH12014502326 B1 PH 12014502326B1
Authority
PH
Philippines
Prior art keywords
amlodipine
losartan
improved stability
composition
composition compromising
Prior art date
Application number
PH12014502326A
Other versions
PH12014502326A1 (en
Inventor
Lee Beom-Jin
Jung Won-Tae
Choi Youn-Woong
Nam Kyu-Yeol
Cho Sang-Min
Park Jin-Ha
Original Assignee
Korea United Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea United Pharm Inc filed Critical Korea United Pharm Inc
Publication of PH12014502326A1 publication Critical patent/PH12014502326A1/en
Publication of PH12014502326B1 publication Critical patent/PH12014502326B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed herein is a composition comprising amlodipine and lozartan, and having improved stability.
PH12014502326A 2012-04-17 2014-10-17 A composition compromising amlodipine and losartan having an improved stability PH12014502326B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120039708A KR101392364B1 (en) 2012-04-17 2012-04-17 Pharmaceutical composition comprising amlodipine and losartan having an improved stability
PCT/KR2013/003231 WO2013157840A1 (en) 2012-04-17 2013-04-17 Composite composition having improved stability and containing amlodipine and rozaltan

Publications (2)

Publication Number Publication Date
PH12014502326A1 PH12014502326A1 (en) 2015-01-12
PH12014502326B1 true PH12014502326B1 (en) 2015-01-12

Family

ID=49383725

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014502326A PH12014502326B1 (en) 2012-04-17 2014-10-17 A composition compromising amlodipine and losartan having an improved stability

Country Status (6)

Country Link
KR (1) KR101392364B1 (en)
CN (1) CN104394865B (en)
BR (1) BR112014025956B1 (en)
PH (1) PH12014502326B1 (en)
RU (1) RU2628538C2 (en)
WO (1) WO2013157840A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102369607B1 (en) * 2014-09-30 2022-03-03 한미약품 주식회사 Solid Pharmaceutical Composition Comprising Amlodipine and Losartan
KR101914930B1 (en) * 2015-03-31 2018-11-05 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
KR20200143914A (en) * 2019-06-17 2020-12-28 주식회사유한양행 A pharmaceutical composition in a multi-layered tablet form comprising amlodipine or its salt and chlorthalidone its salt

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050209288A1 (en) * 2004-01-12 2005-09-22 Grogan Donna R Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use
KR101247583B1 (en) * 2006-12-08 2013-03-26 한미사이언스 주식회사 Pharmaceutical composition comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof
MA33056B1 (en) * 2009-01-23 2012-02-01 Hanmi Holding Co Ltd A solid pharmaceutical formula including amlodipine, losartan and how it is made
CN101708159B (en) * 2009-12-04 2011-06-15 中牧实业股份有限公司 Preparation method for heat-sensitive medicament suspension
KR101270751B1 (en) * 2010-05-06 2013-06-07 (주)비씨월드제약 Composition for the gastric retention and controlled release of therapeutic agents

Also Published As

Publication number Publication date
RU2628538C2 (en) 2017-08-18
WO2013157840A1 (en) 2013-10-24
KR101392364B1 (en) 2014-05-07
RU2014145827A (en) 2016-06-10
CN104394865B (en) 2016-11-09
KR20130117048A (en) 2013-10-25
PH12014502326A1 (en) 2015-01-12
CN104394865A (en) 2015-03-04
BR112014025956B1 (en) 2019-10-29

Similar Documents

Publication Publication Date Title
HK1208443A1 (en) 2,3-benzodiazepines 23-
HK1204326A1 (en) Enediyne compounds, conjugates thereof, and uses and methods therefor
IL234014A0 (en) Cycloalkane derivatives, compositions comprising same and uses thereof
MY169141A (en) Biodegradable compositions, methods and uses thereof
MX338711B (en) Pyrrolobenzodiazepines and conjugates thereof.
EP2849790A4 (en) Drug-conjugates, conjugation methods, and uses thereof
IN2012DN06714A (en)
HK1197242A1 (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines -56--4h-[13]
HK1212700A1 (en) Dihydropyridazine-3,5-dione derivative -35-
GEP201706739B (en) Compositions comprising vortioxetine and donepezil
IL233682A0 (en) Substituted phenylazole derivatives, compositions comprising same and uses thereof
IL280316B (en) Bolaamphiphilic compounds, compositions and uses thereof
PH12014502326B1 (en) A composition compromising amlodipine and losartan having an improved stability
IL237542A0 (en) Bolaamphiphilic compounds, compositions and uses thereof
EP3003298A4 (en) Anti-fibrogenic compounds, methods and uses thereof
IL237540B (en) Bolaamphiphilic compounds, compositions and uses thereof
IL237538A0 (en) Bolaamphiphilic compounds, compositions and uses thereof
IL237539A0 (en) Bolaamphiphilic compounds, compositions and uses thereof
UA78284U (en) 5,11- dibenzyl -8-thioxo-13-(2-chlorophenyl)-3,5,7,11- tetraazatricyclo[7.3.1.02,7]tridec-2-ene-1,9-dicarbonitrile
UA71429U (en) Hepatoprotector
AU2012902941A0 (en) Improved, Aesthetically Devices
UA70540U (en) Degradable polymeric composition
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA78285U (en) N- methylmorpholinium 4-(4-ethoxyphenyl)-2-oxo-5-cyano-1,2,3,4-tetrahydropyridine-6-thiolate